Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: RE: share buyback......limerickhook,...... ads..

RE: share buyback......limeric... ads..

posted on Sep 07, 2006 11:33AM
The warrant buyback program is based upon an agreement which calls for a structured series of warrant redemptions over a period of several months, beginning in February 2006. ``Under the terms of this agreement we have the right but not the obligation to redeem up to 2 million warrants per month,`` Pohl continued, ``and we are pleased to have negotiated a redemption price that is equal to each applicable volume weighted average monthly trading price for Patriot`s shares less the exercise price for the first 10 million warrants covered by this agreement.`` The price and terms applicable to the redemption of the other 10 million warrants will be determined by mutual agreement of the parties.

A spokesman for Lincoln Ventures, LLC and Swartz Private Equity, LLC, announced that ``Lincoln and Swartz are pleased with the progress of Patriot`s intellectual property enforcement program through its joint venture portfolio partner, The TPL Group. We have confidence in their program to secure additional licensing transactions with users of the patented technologies of Patriot and TPL, and the potential for sustained revenue to the Company.``

``At Patriot`s request,`` the spokesman continued, ``both Lincoln and Swartz have agreed to convert all of their outstanding Patriot Scientific debentures into shares of common stock. These conversions will result in our beneficial ownership exceeding 5% of the issued and outstanding shares of Patriot, and as a result we will make all appropriate SEC filings as to the future disposition of our holdings of the Company`s common stock. We trust that these actions will support Patriot Scientific in its growth as Patriot and TPL accelerate their worldwide licensing of the jointly owned MMP Portfolio.``

The action by Patriot Scientific to retire the debentures and to also buy back what could amount to approximately 20 percent of the company`s total outstanding stock warrants at this juncture was driven by the same impetus that has guided other strategic reorganizational moves that began in 2005. Last year the Company changed both its executive team and the Company`s strategic direction, including the signing of a significant agreement with The TPL Group regarding joint ownership and marketing of its patent portfolio.

Share
New Message
Please login to post a reply